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Abstract
Background: The aim of this study was to investigate the effect of a lifestyle intervention in obesity on the soluble
form of the activated leukocyte cell adhesion molecule (sALCAM) and its association with metabolic parameters.
Methods: Twenty-nine obese subjects selected from the OPTIFAST®52 program. This program consisted into 2
crucial phases: an initial 12-week active weight reduction phase, followed by a 40-week weight maintenance phase.
At baseline, after 12 weeks and at the end of the program, fasting glucose and insulin, total cholesterol, LDL-C,
HDL-C, triglycerides, adiponectin, leptin, high sensitivity CRP, sALCAM, homeostasis model assessment-estimated
insulin resistance (HOMA-IR) and leptin-to-adiponectin-ratio were determined. Oral glucose tolerance test (OGTT)
was performed when indicated.
Results: At baseline, the serum concentration of sALCAM was increased and correlated positively with HOMA-IR
and negatively with age. At the end of the program, sALCAM concentrations decreased significantly. Multivariate
analysis showed that sALCAM significantly correlated with age, glucose concentration after 2 h OGTT and the
HOMA-IR. A higher decrease of HOMA-IR during the study was observed in subjects with higher concentration of
sALCAM at baseline.
Conclusions: sALCAM might be a novel biomarker in obesity that correlates and predicts insulin sensitivity
improvement and that can be affected by lifestyle intervention.
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Background
Obesity is considered a major risk factor for cardiovas-
cular diseases, type 2 diabetes, several cancers as well as
musculoskeletal disorders [1]. There is agreement within
the field that chronic systemic inflammation is associ-
ated with insulin resistance in obesity [2]. However a
molecular mechanism that explains the causality be-
tween the two, particularly within the context of obesity,
has yet to be established. In this respect, new biomarkers
that can predict inflammation and insulin resistance in
obesity need to be further investigated.
Recently, it was demonstrated in a model of delayed
type hypersensitivity, that the activated leukocyte cell ad-
hesion molecule (ALCAM/CD166) promotes inflamma-
tion by binding the danger-associated molecular pattern
(DAMP) molecule, S100B leading to activation of NF-κB
[3]. ALCAM showed close structural homology with the
receptor for AGEs (RAGE) and it was shown that each
receptor could functionally substitute the other in re-
sponse to S100B [3]. It has previously been shown that
an inverse association exists between the soluble form of
RAGE (sRAGE) and body mass index (BMI) [4].
Analogous to sRAGE, sALCAM represents the proteo-
lytic cleavage of the ectodomain of the full receptor by “A
Disintegrin and Metalloproteinase Domain 17/Tumor Ne-
crosis Factor α Converting Enzyme” (ADAM17/TACE)
[5]. The function of sALCAM has been previously studied
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by means of recombinant isoforms and ALCAM-IgG-Fc
chimeras, which were able to inhibit cell-cell adhesion and
to promote and/or inhibit cell migration and has been
proposed as a biomarker in several cancers [6, 7]. In vitro
studies have shown that sALCAM is involved in ALCAM-
dependent and –independent immune responses upon in-
flammatory stimulation and that endothelial expression of
ALCAM is induced by hypercholesterolemia [8, 9]. This
would suggest sALCAM as a potential biomarker of the
innate immune system in inflammation-associated disor-
ders such as hypercholesterolemia, diabetes and obesity.
The aim of this study was to investigate the metabolic
role of sALCAM in severely obese patients and whether
a 52-week lifestyle intervention program would modu-
late sALCAM serum concentration.
Methods
Study population
This study involved 29 subjects (18 women and 11 men)
randomly and retrospectively selected from the OPTI-
FAST®52 program (franchise holder Nestlé Inc.,
Switzerland) at the University Hospital of Heidelberg.
The OPTIFAST®52 program is a 52-week lifestyle inter-
vention that has been previously described [10]. For the
purpose of this study, patient samples and data were
studied at three time-points: at the beginning of the pro-
gram (T0), after 12-week of active weight loss phase
through a low-calorie formula-diet (T1) and after 40-
week of weight maintenance phase (T2). Subjects had
the following comorbidities: hypertension (N = 15), insu-
lin resistance (N = 25), arthrosis (N = 7), substituted
hypothyroidism (N = 6), hyperlipidemia (N = 4), Type 2
Diabetes mellitus (N = 3), obstructive sleep apnea syn-
drome (N = 3), non-alcoholic fatty liver disease (N = 3)
and anemia, chronic obstructive pulmonary disease,
hyperthyroidism, polycystic ovary syndrome (each N =
1). With respect to medication, 18 subjects were under
antihypertensive medication, whereas ten subjects took
oral antidiabetic drugs, three were under insulin treat-
ment and four were taking statins. Written informed
consent was given by participants for their clinical re-
cords and blood samples to be used in this study. This
full study and the use of archival material from patients
were specifically approved from the “Ethics Committee”
of the Medical Faculty of the University of Heidelberg in
compliance with national guidelines and the declaration
of Helsinki. Full clinical characteristics of the subjects at
baseline are given in Table 1.
Anthropometrical and laboratory measurements
Height, weight and blood pressure were measured regu-
larly using standard method. Body mass index (BMI)
was consistently calculated by the formula: BMI =
Weight (kg)/Height (m)2. Blood samples were collected
at described time-points (T0, T1 and T2) and immedi-
ately analyzed. Serum samples were stored at −80 °C for
further analysis. Fasting glucose and insulin, total choles-
terol (T-Cholesterol), low density lipoprotein (LDL),
high density lipoprotein (HDL), triglycerides, adiponec-
tin, leptin and high sensitivity CRP (hsCRP) levels were
measured in the central laboratory of the University
Hospital of Heidelberg. The oral glucose tolerance test
(OGTT) was performed at the Endocrinology Ambu-
lance of the University Hospital of Heidelberg and glu-
cose level after 2 h was measured at the central
laboratory. Homeostasis model assessment-estimated in-
sulin resistance (HOMA-IR) was calculated by the for-
mula: HOMA-IR = fasting Glucose [in mg/dl]*fasting
Insulin [in mU/l]/405. Leptin-to-Adiponectin Ratio
(LAR) was calculated by the formula: LAR = Leptin/Adi-
ponectin. The serum concentration of sALCAM was de-
termined by enzyme linked immuno-sorbent assay
(ELISA) (DY656, R&D Systems, USA) according to the
manufacturer’s protocol with a sample dilution of 1:800
in triplicate.
Statistical analysis
SPSS version 20.0 (IBM SPSS, Inc. Armonk, NY) and
GraphPad Prism version 5.00 for Windows (GraphPad
Software, San Diego California USA) were used to
analyze the collected data. Where indicated, values are
given as mean and SE. Due to small sample size, normal
or other exact distribution could not be specified,
Table 1 Clinical characteristics of patients at baseline
Characteristics Value (n = 29)
Age (years) 42.3 ± 2.2
Gender (female/male) 18/11
BMI (kg/m2) 46.4 ± 1.7
History of:
Hypertension (yes, n [%]) 15 [50]
Insulin resistance (yes, n [%]) 25 [83]
Diabetes Mellitus Type 2 (yes, n [%]) 3 [10]
Hypercholesterolaemia (yes, n [%]) 4 [13]
Allergies (yes, n [%]) 6 [20]
Arthrosis (yes, n [%]) 7 [23]
Hypothyroidism (yes, n [%]) 6 [20]
Nonalcoholic Fatty Liver Disease (yes, n [%]) 3 [10]
Obstructive Sleep Apnea (yes, n [%]) 3 [10]
Medication:
Antihypertensive (yes, n [%]) 18 [60]
Oral hypoglycemic (yes, n [%]) 10 [33]
Insulin (yes, n [%]) 3 [10]
Statins (yes, n [%]) 4 [13]
Data represent mean ± SE
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therefore non-parametric statistical tests were applied.
Univariate Spearman’s rank correlation coefficient (R)
was used for correlation analysis at baseline. Friedman
test was used for overall comparison between measure-
ments and where significant Wilcoxon signed-rank test
was applied for comparing single point measurements.
Repeated measurements of identified parameters in
different subjects were analyzed as panel data. Therefore a
multivariate linear regression model for panel data
was created by the stepwise inclusion of all explana-
tory parameters of sALCAM level, considering also
joint effects of parameters. Results were expressed as
standardized correlation coefficient (β) under a 95 %
confidence interval. The likelihood-ratio test on the
significance of the model was calculated. Collinearity
analysis was also performed. Mann-Whitney test was
applied to compare sALCAM mean level at baseline
among the quartiles of changes in HOMA-IR
(ΔHOMA-IR). Values of P < 0.05 were considered
statistically significant.
Results
A total of 29 subjects (18 female and 11 male) were part
of this study (Table 1). At baseline, subjects were severely
obese with a mean BMI of 46.4 ± 1.7 kg/m2. Half of the
subjects suffered from hypertension with a MAP of 109 ±
2.6 mmHg and were treated accordingly with lowering
blood pressure medication. With respect to glucose me-
tabolism, 3 of the subjects had diabetes mellitus type 2.
The remaining 48 % had impaired fasting glucose and
12 % had impaired glucose tolerance according American
Diabetes Association (ADA) criteria [11]. 83 % of patients
had insulin resistance, according to the HOMA-IR
with a cut-off value of 2.3 [12]. Adiponectin levels
were decreased, whereas leptin and LAR were increased
(4.8 ± 0.4 μg/ml, 54.1 ± 5.9 μg/l and 12.7 ± 1.4 respect-
ively), which are considered predictors of insulin sen-
sitivity [13, 14]. hsCRP levels at baseline were
increased as a sign of increased non-specific inflam-
mation (Table 2).
All the subjects tolerated the lifestyle intervention pro-
gram well. At the end of the study, whilst decreased sig-
nificantly by 22 %, the mean BMI was 36.3 kg/m2, which
would still be classified as Obesity class II, according to
WHO criteria. However the metabolic parameters had
improved significantly after 52 weeks (Table 2). Glucose
metabolism and insulin sensitivity were improved and
the dose of medication taken was reduced in 73 % of the
subjects treated with oral antidiabetic drugs. MAP de-
creased significantly after 12 weeks and at the end of the
study the antihypertensive medication was reduced in
78 % of the subjects treated. Half of the subjects treated
with lipid lowering agents had also reduced their medi-
cation. The respective medications were reduced starting
from week 12. These results are consistent with previous
studies on similar lifestyle intervention programs [15].
sALCAM serum concentration at baseline was in-
creased when compared to serum concentration of sAL-
CAM in healthy subjects, reported in previous studies
[5, 6]. sALCAM levels at baseline correlated negatively
with the age of the subjects (R = −0.51. P < 0.01) (Fig. 1a)
and positively with the HOMA-IR (R = 0.48, P < 0.01)
(Fig. 1b) whereas no correlation between sALCAM and
BMI was observed (data not shown). At the end of the
program, the concentration of sALCAM had decreased
significantly by 11 % as compared to baseline (224.0 ±
13.7 ng/ml vs. 199.5 ± 14.0 ng/ml) (Fig. 2). Multivariate
analysis for panel data showed that during the study
serum concentrations of sALCAM significantly corre-
lated with age (β = −3.44, P = 0.01), glucose concentra-
tion after 2 h OGTT (2 h-OGTT, β = 0.37, P = 0.008)
and the HOMA-IR (β = 1.52, P = 0.04) (Table 3). How-
ever, sALCAM levels did not correlate significantly with
BMI, LAR and hsCRP and all joint effects of the param-
eters were found to be non-significant. The likelihood-
ratio test of the model was significant (LR = 590, df =
15). Collinearity analysis showed no significant multicol-
linearity (VIF < 3). Furthermore, baseline levels of sAL-
CAM were compared among subjects with differences
in the HOMA-IR at the end of the study. For this pur-
pose subjects were divided according to the quartiles of
the reduction of HOMA-IR between baseline and end of
the program (ΔHOMA-IR). Baseline levels of sALCAM
were found significantly higher in subjects with reduc-
tion of HOMA-IR belonging to the fourth quartile when
compared to those belonging to the first quartile (191.6
± 30.1 ng/ml vs. 254.1 ± 29.1 ng/ml, P < 0.05) (Fig. 3).
This would suggest sALCAM level at baseline as a bio-
marker for predicting the metabolic effect of lifestyle
intervention programs on improving insulin sensitivity.
When age in between the two groups was compared it
was found that the subjects with the higher HOMA-IR
improvement and higher sALCAM levels at baseline
were younger, as it is excepted since sALCAM level cor-
related negatively with age (37 ± 2,3 years vs. 50 ± 3 years,
P = 0,005).
Discussion
In this study, the effect of weight reduction in severely
obese patients on serum sALCAM, a soluble isoform of
a recently described PRR, was investigated. It was shown
that sALCAM was increased in severely obese patients
and decreased significantly during a lifestyle intervention
program. The levels of sALCAM measured in this study
were higher when compared to levels of sALCAM in
healthy subjects measured in previous studies [5–7].
sALCAM represents the proteolytic cleavage of the full
receptor and has been proposed as a biomarker for
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different cancers [5–7]. In the context of obesity there is
lack of studies on the potential role of sALCAM. In pre-
vious work by this group it was found that serum sAL-
CAM is increased in subjects with metabolic disorders,
such as type 2 diabetes and familiar hypercholesterol-
emia (data in review). Increased shedding of the recep-
tor could indicate a protective mechanism where
sALCAM acts as a decoy receptor by inhibiting ligand
binding to the transmembrane glycoprotein ALCAM
and therefore preventing its activation. Similiar function
was observed in previous work in our group regarding
scavenging of RAGE ligands by sRAGE which led to re-
duced delayed-type hypersensitivity even in mice lacking
RAGE. In this way we were able to identify ALCAM as
a close functional and structural homologue of RAGE
[3]. Further studies are required to determine whether
the scavenging of ALCAM or RAGE ligands by sAL-
CAM is functionally related to the inhibition of detri-
mental ALCAM signalling in obesity. Due to the relative
low affinity of the ligands to their respective receptors
however, it seems unlikely since in vivo levels of the li-
gands are significantly lower than the amount required
in vitro for their physiological function [3]. This could
suggest that sALCAM functional role might be primarily
in local tissue rather than in serum and future studies
are needed to investigate tissue expression of sALCAM
and sALCAM-ALCAM interaction in obesity.
No correlation was observed between sALCAM and
BMI during the course of study. However previous stud-
ies have shown that BMI is not a sensitive marker for
obesity-related risk of metabolic disorders [16, 17]. Non-
obese subjects with metabolic disorders and obese
Table 2 Anthropometric and metabolic characteristics of patients during the study
Parameter T0 T1 T2 Friedman Test P(T0-T1) P(T1-T2) P(T0-T2)
Age (years) 42.3 ± 2.2
Gender (female/male) 18/11
BMI (kg/m2) 46.4 ± 1.7 38.3 ± 1.4 36.3 ± 1.4 *** *** * ***
MAP (mmHg) 109.0 ± 2.6 93.4 ± 2.3 103.5 ± 2.4 *** *** * n.s.
Fasting glucose (mg/dl) 110.2 ± 7.0 90.7 ± 2.1 89.7 ± 2.2 *** *** n.s. ***
2 h-Glucose OGTT (mg/dl) 117.9 ± 6.6 117.5 ± 4.7 93.2 ± 3.6 *** n.s. *** ***
HOMA-IR 7.8 ± 1.2 3.3 ± 0.3 3.8 ± 0.5 *** *** n.s. **
T-cholesterol (mg/dl) 192.2 ± 7.6 157.4 ± 5.5 181.0 ± 6.8 *** *** *** n.s.
LDL (mg/dl) 110.3 ± 6.4 98.3 ± 4.5 105.8 ± 5.3 * ** n.s. n.s.
HDL (mg/dl) 53.4 ± 4.4 38.9 ± 1.9 53.8 ± 2.6 *** *** *** n.s.
Triglycerides (mg/dl) 149.5 ± 22.9 100.8 ± 5.2 123.9 ± 30.9 ** *** n.s. **
Adiponectin (μg/ml) 4.8 ± 0.4 6.7 ± 0.5 7.9 ± 0.7 *** *** * ***
Leptin (μg/l) 54.1 ± 5.9 20.5 ± 2.7 32.9 ± 5.8 *** *** ** ***
LAR 12.7 ± 1.4 3.5 ± 0.5 5.7 ± 1.1 *** *** * ***
hsCRP (mg/l) 10.1 ± 2.1 6.1 ± 1.1 3.4 ± 0.8 *** * ** ***
Friedman test was used for overall comparison and where significant Wilcoxon signed test was used for comparison between single point measurements. Data
represent Mean ± SE. *P < 0.05, **P < 0.01, ***P < 0.001, n.s. = non-significant
Fig. 1 Correlation of serum concentration of sALCAM with Age and HOMA-IR at baseline. Serum concentration of sALCAM correlated negatively
with age (a) and positively with HOMA-IR at baseline (b). Univariate Spearman’s rank correlation coefficient (R) was used for correlation analysis.
Values of P < 0.05 were considered statistically significant
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subject with no obesity-associated metabolic complica-
tions have already been published [18]. Instead of BMI
other markers, such as those of obesity-induced insulin
resistance have been investigated extensively [19, 14].
In this study it was shown that sALCAM serum
concentration correlated significantly with the
HOMA-IR as a well-established marker of insulin re-
sistance but no correlation was observed with the
levels of hsCRP, as a nonspecific systemic marker of
inflammation [19, 13, 20]. It has previously been re-
ported in primates that endothelial expression of cell
adhesion molecules, such as VCAM-1 and P-Selectin,
is an early event in diet-induced obesity that occurs
simultaneously with the development of insulin resist-
ance but does not correlate with systemic markers of
inflammation, such as CRP [21]. Whether the
expression of the full receptor ALCAM in endothelial
cells or circulating cells such as macrophages is in-
volved in the molecular mechanism of obesity-
induced insulin resistance requires further investiga-
tion. However it was shown in this study that shed-
ding of ALCAM into the serum of obese patients
predicts the metabolic success of weight reduction
with respect to insulin sensitivity. In this regard pure
chronological age effect in the improvement of insulin
sensitivity is excluded, since previous study has
showed that it is increased adiposity related to aging
that explains the reduction in insulin sensitivity rather
than chronological age itself [22].
A limitation of this study is the small sample of sub-
jects recruited. We acknowledge that the model we
propose explains only the variables that were considered
and there might be other factors influencing the levels of
sALCAM. However the considered variables explain sig-
nificantly part of the changes in sALCAM level. Unex-
plained changes due to non-included factors need to be
further investigated.
Future experimental analysis should provide new in-
sights on the functional role of sALCAM in particu-
larly its involvement in ALCAM-dependent and –
independent immune responses in low-grade inflam-
matory state and whether the scavenging of ALCAM
ligands by sALCAM is functionally related to the in-
hibition of ALCAM signalling.
Fig. 2 Serum concentration of sALCAM during the study. sALCAM
serum concentration decreased significantly at the end of the
program. Friedman test was used for overall comparison between
measurements and where significant Wilcoxon signed-rank test was
applied for comparing single point measurements.
*P < 0.05, **P < 0.01
Table 3 Multivariate linear regression analysis for sALCAM as
dependent variable through the study
Independent
variable
sALCAM
β Coefficient (95 % CI) P value
Age −3.44 (−5.95:−0.92) 0.01
BMI −0.53 (−2.46:1.40) 0.58
2 h- OGTT 0.37 (0.11:0.64) 0.008
HOMA-IR 1.52 (0.01:3.02) 0.04
LAR 0.47 (−0.89:1.83) 0.48
hsCRP 0.35 (−0.96:1.67) 0.58
Multivariate linear regression model for panel data was created by the
stepwise inclusion of explanatory parameters of sALCAM level, considering
also joint effects of parameters. Results were expressed as standardized
correlation coefficient (β) under a 95 % confidence interval. Values of P < 0.05
were considered statistically significant and are presented in boldface
Fig. 3 sALCAM serum concentration at baseline and decrease of
HOMA-IR (ΔHOMA-IR). Subjects who showed a higher decrease of
HOMA-IR had higher serum concentration of sALCAM at baseline. Data
are shown as quartiles of the reduction of HOMA-IR (ΔHOMA-IR) and
mean levels of sALCAM at baseline with error bars showing SE. Wilcoxon
signed-rank test was applied for comparing single point
measurements. *P< 0.05
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Conclusions
This study identifies for the first time sALCAM as a
novel biomarker in severe obesity. Serum concentration
of sALCAM was not only increased in severely obese
subjects but also decreased significantly through a life-
style intervention program. Moreover, serum sALCAM
levels correlated positively with levels of HOMA-IR and
predicted the success of the program in improving insu-
lin sensitivity. sALCAM might be a novel biomarker of
immune responses in obesity which can be significantly
affected by lifestyle intervention programs.
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